Diagnostics

Bioassays company announces U.S. Army contract, new kinase Activity Assays

Published in Gene Therapy Weekly, November 11th, 2004

QTL Biosystems announced the introduction of its QTL LightSpeed Kinase platform and four new kinase Activity Assays.

The kinase platform is built utilizing QTL's patented superquenching polymer technology, which delivers universal mix and measure assays that do not require antibodies or radioactive labels. The platform is compatible with standard fluorescent instrumentation and works with peptide or protein substrates. The kinase assays are used to target the molecular processes of the cell and to develop new future treatments for cancer, diabetes and other diseases.

The first four kinase assays are:

-PKC-alpha, targeted at drugs...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry